Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TADalafil in Early-Stage Parkinson’s Disease (TAD-PD)
2025-521819-39-00Phase 2Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tadalafil in Parkinson's disease (PD), sponsored by Amsterdam University Medical Center. Primary endpoint: Change in motor symptoms (MDS-UPDRS Part III). Planned start Jan 2026; status: authorised.
02
Drugs
tadalafil
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2025-521819-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521819-39-00.